Nash Pharmaceuticals Announces 84% Reduction of Fibrosis by Additional Lead Compound in Second Pre-Clinical Study for Non-Alcoholic Fatty Liver Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., announces that its lead compound for non-alcoholic steatohepatitis (NASH)... Read More
Nash Pharmaceuticals Announces Positive Pre-Clinical Results From a Second Study for Chronic Kidney Disease
Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that in a new recent... Read More
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease (Globe Newswire)
Nash Pharmaceuticals Inc., a wholly owned subsidiary of UF startup Breathtec Biomedical Inc., is pleased to announce that in a recent in... Read More
